This efficacy of BSO was not seen in BRCA1 carriers who predominantly develop ER‐ cancers, although reduction of contralateral breast cancer with tamoxifen was observed, warranting longer follow‐up in this high‐risk group (Lakhani et al, 2005; Evans et al, 2018). The gene discussed is BRCA1; the disease is breast carcinoma.